Portal de Periódicos da CAPES

Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma

2021; Elsevier BV; Volume: 32; Issue: 6 Linguagem: Inglês

10.1016/j.annonc.2021.03.006

1569-8041

Robert V. Rawson, Chandra Mani Adhikari, Carolien Bierman, Serigne Lo, Elena Shklovskaya, Elisa A. Rozeman, Alexander M. Menzies, Alexander C.J. van Akkooi, Kerwin F. Shannon, Maria Gonzalez, Alexander Guminski, M.T. Tetzlaff, Jonathan R. Stretch, Hanna Eriksson, Johannes V. van Thienen, Michel W.J.M. Wouters, John B.A.G. Haanen, W. Martin C. Klop, Charlotte L. Zuur, Winan J. van Houdt, Omgo E. Nieweg, Sydney Ch’ng, Helen Rizos, Robyn P.M. Saw, Andrew J. Spillane, James S. Wilmott, Christian U. Blank, Georgina V. Long, Bart A. van de Wiel, Richard A. Scolyer,

Immunotherapy and Immune Responses

•Eighty-three lymph node dissections following neoadjuvant immunotherapy for stage III metastatic melanoma were assessed.•There was strong reproducibility in assessment of INMC pathological response category and percentage of viable melanoma.•High fibrosis was associated with a lack of recurrence and increased RFS, representing a possible biomarker.•Two different scoring systems of response were assessed and both scoring systems correlated with a lack of recurrence.•High fibrosis was also associated with increased levels of B cells within the tumour bed. BackgroundGuidelines for pathological evaluation of neoadjuvant specimens and pathological response categories have been developed by the International Neoadjuvant Melanoma Consortium (INMC). As part of the Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab (OpACIN-neo) clinical trial of neoadjuvant combination anti-programmed cell death protein 1/anti-cytotoxic T-lymphocyte-associated protein 4 immunotherapy for stage III melanoma, we sought to determine interobserver reproducibility of INMC histopathological assessment principles, identify specific tumour bed histopathological features of immunotherapeutic response that correlated with recurrence and relapse-free survival (RFS) and evaluate proposed INMC pathological response categories for predicting recurrence and RFS.Patients and methodsClinicopathological characteristics of lymph node dissection specimens of 83 patients enrolled in the OpACIN-neo clinical trial were evaluated. Two methods of assessing histological features of immunotherapeutic response were evaluated: the previously described immune-related pathologic response (irPR) score and our novel immunotherapeutic response score (ITRS). For a subset of cases (n = 29), cellular composition of the tumour bed was analysed by flow cytometry.ResultsThere was strong interobserver reproducibility in assessment of pathological response (κ = 0.879) and percentage residual viable melanoma (intraclass correlation coefficient = 0.965). The immunotherapeutic response subtype with high fibrosis had the strongest association with lack of recurrence (P = 0.008) and prolonged RFS (P = 0.019). Amongst patients with criteria for pathological non-response (pNR, >50% viable tumour), all who recurred had ≥70% viable melanoma. Higher ITRS and irPR scores correlated with lack of recurrence in the entire cohort (P = 0.002 and P ≤ 0.0001). The number of B lymphocytes was significantly increased in patients with a high fibrosis subtype of treatment response (P = 0.046).ConclusionsThere is strong reproducibility for assessment of pathological response using INMC criteria. Immunotherapeutic response of fibrosis subtype correlated with improved RFS, and may represent a biomarker. Potential B-cell contribution to fibrosis development warrants further study. Reclassification of pNR to a threshold of ≥70% viable melanoma and incorporating additional criteria of 50% viable tumour), all who recurred had ≥70% viable melanoma. Higher ITRS and irPR scores correlated with lack of recurrence in the entire cohort (P = 0.002 and P ≤ 0.0001). The number of B lymphocytes was significantly increased in patients with a high fibrosis subtype of treatment response (P = 0.046). There is strong reproducibility for assessment of pathological response using INMC criteria. Immunotherapeutic response of fibrosis subtype correlated with improved RFS, and may represent a biomarker. Potential B-cell contribution to fibrosis development warrants further study. Reclassification of pNR to a threshold of ≥70% viable melanoma and incorporating additional criteria of <10% fibrosis subtype of response may identify those at highest risk of recurrence, but requires validation.